ProCE Banner Activity

CARISEL: Clinical Outcomes by Implementation Strategy of Patients Receiving LA CAB + RPV in European Healthcare Settings

Slideset Download
Conference Coverage
Long-acting cabotegravir plus rilpivirine was effective and well tolerated at 12 months regardless of implementation support in this phase IIIb study.

Released: October 26, 2022

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare